Determination of toosendanin in rat plasma by ultra‐performance liquid chromatography–electrospray ionization–mass spectrometry and its application in a pharmacokinetic study |
| |
Authors: | Xintang Wang Changhong Wang Zhengtao Wang |
| |
Affiliation: | 1. Department of Pharmacognosy, China Pharmaceutical University, , Nanjing, 210038 China;2. The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, , Shanghai, 201210 People's Republic of China;3. Shanghai R&D Centre for Standardization of Chinese Medicines, , Shanghai, 201210 People's Republic of China |
| |
Abstract: | Toosendanin (TSN) is a major triterpenoid existing in Melia toosendan, which has been used as a digestive tract parasiticide and insecticide but with serious hepatotoxicity. An ultra‐performance liquid chromatography–electrospray ionization–mass spectrometry method was developed for determination of TSN in rat plasma. Plasma samples were separated on Acquity UPLCTM BEH C18 column with acetonitrile and water as flow phase by gradient elution and determined by quadrupole mass spectrometer in negative selective ion monitoring mode. Usolic acid was used as internal standard. The calibration curves were linear over 0.02–3.0 µg/mL for TSN with a lower limit of quantification (LLOQ) of 20 ng/mL in rat plasma. The extraction recoveries of TSN were within 74.3–80.7% with an accuracy of 94.5–108.9%. The intra‐ and inter‐day precision values of the assay at three quality control levels were 8.8–13.8% and <13.9% at LLOQ level, respectively. The method was successfully applied to a pharmacokinetic study of TSN in rats after a single intravenous and oral administration of 2 and 60 mg/kg. The shorter Tmax, higher Vd and Cl of TSN after oral administration indicated that TSN could be absorbed, distributed and eliminated quickly in rats in vivo. The absolute bioavailability of TSN after oral administration was 9.9%. Copyright © 2012 John Wiley & Sons, Ltd. |
| |
Keywords: | toosendanin pharmacokinetics UPLC‐ESI/MS rat plasma |
|
|